TY - JOUR
T1 - Barriers and facilitators to implementing telehealth services during the COVID-19 pandemic
T2 - A qualitative analysis of interviews with cystic fibrosis care team members
AU - Van Citters, Aricca D.
AU - Dieni, Olivia
AU - Scalia, Peter
AU - Dowd, Christopher
AU - Sabadosa, Kathryn A.
AU - Fliege, Jill D.
AU - Jain, Manu
AU - Miller, Robert W.
AU - Ren, Clement L.
N1 - Funding Information:
This paper is part of a Supplement supported by the Cystic Fibrosis Foundation.
Funding Information:
This work was supported by the Cystic Fibrosis Foundation. A grant was also provided by the Cystic Fibrosis Foundation to The Dartmouth Institute for Health Policy and Clinical Practice (NELSON20QI0).
Publisher Copyright:
© 2021
PY - 2021/12
Y1 - 2021/12
N2 - Background: The COVID-19 pandemic forced cystic fibrosis (CF) care programs to rapidly shift from in-person care delivery to telehealth. Our objective was to provide a qualitative exploration of facilitators and barriers to: 1) implementing high-quality telehealth and 2) navigating reimbursement for telehealth services. Methods: We used data from the 2020 State of Care CF Program Survey (n=286 U.S. care programs) administered in August-September to identify two cohorts of programs, with variation in telehealth quality (n=12 programs) and reimbursement (n=8 programs). We conducted focus groups and semi-structured interviews with CF program directors and coordinators in December 2020, approximately 9 months from onset of the pandemic. We used the Consolidated Framework for Implementation Research to identify facilitators and barriers of implementation, and inductive thematic analysis to identify facilitators and barriers of reimbursement. Results: Factors differentiating programs with greater and lower perceived telehealth quality included telehealth characteristics (perceived advantage over in-person care, cost, platform quality); external influences (needs and resources of those served by the CF program), characteristics of the CF program (compatibility with workflows, relative priority, available resources); characteristics of team members (individual stage of change), and processes for implementation (engaging patients and teams). Reimbursement barriers included documentation to optimize billing; reimbursement of multi-disciplinary team members, remote monitoring, and telephone-only telehealth; and lower volume of patients. Conclusions: A number of factors are associated with successful implementation and reimbursement of telehealth. Future efforts should provide guidance and incentives that support telehealth delivery and infrastructure, share best practices across CF programs, and remove barriers.
AB - Background: The COVID-19 pandemic forced cystic fibrosis (CF) care programs to rapidly shift from in-person care delivery to telehealth. Our objective was to provide a qualitative exploration of facilitators and barriers to: 1) implementing high-quality telehealth and 2) navigating reimbursement for telehealth services. Methods: We used data from the 2020 State of Care CF Program Survey (n=286 U.S. care programs) administered in August-September to identify two cohorts of programs, with variation in telehealth quality (n=12 programs) and reimbursement (n=8 programs). We conducted focus groups and semi-structured interviews with CF program directors and coordinators in December 2020, approximately 9 months from onset of the pandemic. We used the Consolidated Framework for Implementation Research to identify facilitators and barriers of implementation, and inductive thematic analysis to identify facilitators and barriers of reimbursement. Results: Factors differentiating programs with greater and lower perceived telehealth quality included telehealth characteristics (perceived advantage over in-person care, cost, platform quality); external influences (needs and resources of those served by the CF program), characteristics of the CF program (compatibility with workflows, relative priority, available resources); characteristics of team members (individual stage of change), and processes for implementation (engaging patients and teams). Reimbursement barriers included documentation to optimize billing; reimbursement of multi-disciplinary team members, remote monitoring, and telephone-only telehealth; and lower volume of patients. Conclusions: A number of factors are associated with successful implementation and reimbursement of telehealth. Future efforts should provide guidance and incentives that support telehealth delivery and infrastructure, share best practices across CF programs, and remove barriers.
KW - Barriers
KW - Cystic fibrosis
KW - Facilitators
KW - Implementation
KW - Telehealth
UR - http://www.scopus.com/inward/record.url?scp=85121290439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121290439&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2021.09.004
DO - 10.1016/j.jcf.2021.09.004
M3 - Article
C2 - 34930537
AN - SCOPUS:85121290439
SN - 1569-1993
VL - 20
SP - 23
EP - 28
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
ER -